Pune: Medtronic plc, a global leader in healthcare technology, has announced the launch of a new Medtronic Global Capability Centre (GCC) in Pune, India, dedicated to advancing its Diabetes business.
With a $50 million investment spread over five years, the centre is set to become a strategic innovation hub for customer care, digital technologies, analytics, and operational excellence.
Also Read: Bengaluru, Chennai, Hyderabad Account for 64 Per Cent of GCC Office Leasing in Q1 2025
The Medtronic Diabetes GCC aims to create over 300 service and software roles in its first year, with plans to double its workforce within the next four years. The initiative underscores Medtronic’s long-term vision to transform diabetes care through technology, intelligent systems, and personalized support.
“India, and Pune in particular, offer exceptional talent and technology capabilities. This GCC will help us simplify diabetes management and expand our global impact,” said Que Dallara, EVP & President, Medtronic Diabetes.
Medtronic Global Capability Centre: Key Highlights
- $50 million investment over five years to build and scale the GCC
- 300+ jobs in year one; projected to double in four years
- Focus areas: advanced analytics, digital technology, patient support, and financial services
- Strengthens Medtronic’s global leadership in diabetes care innovation
- Reinforces India’s growing role as a GCC hub, with Pune emerging as a preferred location
“This centre reflects our commitment to diabetes transformation and creating local talent opportunities,” added Vijendra Singh, Site Director, Medtronic Diabetes GCC India.
Also Read: Knight Frank: India Tops APAC Office Leasing Market in 2024
The Medtronic Global Capability Centre in Pune aligns with Medtronic’s broader strategy to enhance operational efficiency while contributing to India’s burgeoning $100 billion GCC industry. It also reflects the company’s commitment to India’s healthcare and technology ecosystem.
This Medtronic Global Capability Centre announcement follows Medtronic’s recent decision to spin off its Diabetes business into a standalone publicly traded company, which will be called MiniMed.
